Clinical Trial Update: Regeneron AA Multicenter (Dupilumab) [Phase 2]

View source ↗

Summary

Regeneron's dupilumab is being studied in a multicenter Phase 2 trial for Alopecia Areata. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Emma Guttman | Conditions: Alopecia Areata | Phase 2 | Status: RECRUITING